Urologic Oncology

Molecular basics on Genitourinary Malignancies.- Clinical Aspects and Investigations.-Radiological Investigations in Genitourinary Cancer.- New Imaging Modalities.- Principles of systemic therapy in urologic tumors.- The Emerging Role of immunotherapy in GU-tumors.- Bone targeted therapy.- Clinical Emergencies in Genitourinary Cancers.- Nuclear Medicine in Urological Cancer.- Strategies addressing quality of life: Patient reported outcome and symptoms management.- Pain control in genitourinary cancer patients.- Clinical trials and their principles.- GU malignancies: Prostate Cancer.- Bladder Cancer.- Renal Cancer.- Testicular Cancer.- Penile Cancer.- Other Rare Urologic Malignancies. - Diet and Genitourinary Cancer.- Systemic genitourinary Oncology.

This comprehensive and timely textbook covers all aspects of the evidence-based management of genitourinary cancers and explains the fundamental principles underlying the available diagnostic and treatment approaches, including chemotherapy, radiotherapy, immunotherapy, and surgery. For each type of cancer - prostate, bladder, renal, testicular, and penile, plus rare urologic malignancies - clinical presentation, diagnosis, and treatment strategies are described in detail and information is provided on etiology, epidemiology, risk factors, and pathology, including TNM classification. Careful attention is also devoted to the complications that may be encountered when treating urologic malignancies and to the management of these complications. The text is complemented by the inclusion of numerous high-definition photographs and illustrations. Urologic Oncology will be a valuable reference and source of guidance for all oncologists, urologists and practitioners in related disciplines who treat patients with urologic cancers.

Prof. Dr. med. Axel Merseburger is Professor of Urology and Chairman of the Department of Urology at University Hospital Schleswig-Holstein, Campus Lubeck, Germany. After graduating from Hannover Medical School in 2002, he carried out a residency in surgery and urology at the Eberhard Karls University, in Tubingen, followed by a research fellowship at the Miller School of Medicine, Miami, USA (2006). He became Associate Professor in 2009 and full Professor in 2012 at Hannover Medical School.Professor Merseburger is a member of various uro-oncology organisations and serves as an advisor for the European Association of Urology (EAU) Guideline Group for Renal Cancer and was the Chairman of the EAU Guideline Group for Lasers and Technologies. He acts as reviewer and editorial board member for several urology and oncology indexed journals and is associate editor of the World Journal of Urology and editor in Chief of European Oncology & Haematology Journal.Professor Merseburger's research activity encompasses both molecular and clinical aspects of uro-oncology, with specific interest in biomarkers and prognostic factors for prostate cancer, renal cell carcinoma and transitional cell carcinoma. He has authored and co-authored more than 200 peer-reviewed articles and he is the principal investigator in multiple phase II and III clinical trials.

Prof. Dr. med. Maximilian Burger, F.E.B.U.,MD, is Professor of Urology and Chairman of the Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Germany. He was born in Munich, Germany in 1974 and attended the Medical Schools of the Universities of Ulm and Regensburg and Tulane University, New Orleans, Louisiana, USA graduating in 2000. He underwent urology training at the departments of the Universities of Mainz and Regensburg and was board certified in 2005. In 2007 he was appointed Assistant Professor of Urology by the University of Regensburg. From 2011 to 2013 he was appointed Assistant Professor of Urology by the Julius-Maximilians University of Wurzburg (Chairman Prof. Dr. Riedmiller) serving as Deputy Chairman (Leitender Oberarzt). He was appointed Professor of Urology and Chairman of the department in Regensburg in 2013. His main clinical and academical focus is surgical and medical uro-oncology. He has authored and coauthored numerous papers mainly on bladder and prostate cancer. He is a member of the national German bladder cancer guideline panel (S3) since 2012 and a member of the non-muscle invasive bladder cancer guideline panel of the European Association of Urology (EAU) since 2012 serving as its Vice-Chairman. In 2014, he was elected to the board of the the German Association of Urology (DGU).